Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 6Gliosarcoma 6Glioblastoma 6Endometrial Neoplasms 6Carcinoma, Renal Cell 6Sarcoma 5Brain Neoplasms 5Waldenstrom Macroglobulinemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Hodgkin Disease 4Rhabdomyosarcoma 3Prostatic Neoplasms 3Multiple Myeloma 3Lymphoma, Large B-Cell, Diffuse 3Glioma 3Breast Neoplasms 3Unspecified Childhood Solid Tumor, Protocol Specific 2Unspecified Adult Solid Tumor, Protocol Specific 2Ovarian Neoplasms 2Osteosarcoma 2Oligodendroglioma 2Neoplasms 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma 2

Interventions

Magnetic Resonance Spectroscopy 7X-Rays 6Vincristine 6Phantoms, Imaging 6Cyclophosphamide 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Ifosfamide 5Etoposide 5Biopsy 5Temozolomide 4Radiotherapy 4Doxorubicin 4Dactinomycin 4Topotecan 3Melphalan 3Irinotecan 3Filgrastim 3Carboplatin 3Busulfan 3ulixertinib 2tipifarnib 2tazemetostat 2tanespimycin 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ixabepilone 2ivosidenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neuroectodermal Tumors, Primitive, Peripheral × temsirolimus × Clear all
NCT01614795 2018-12-11

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
46 enrolled 13 charts
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Neuroectodermal Tumors, Primitive, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡